Featured Stock Overview: Repros Therapeutics Inc. (RPRX)

If the stock price is unchanged its weighted alpha will be smaller. The company operates in the Healthcare sector with a market capitalization of 19260. For the past 5 years, the company's revenue has grown 81.8%, while the company's earnings per share has grown 0%. The stock's short float is around of 2.23% and short ratio is 1.02. The mean target price as estimated by the analysts for the company has been recorded at $5.50. Repros Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.48. The volume of 16.41 Million shares climbed down over an trading activity of 798.29 Million shares. Unusual volume shows something has likely happened in the stock-such as a news release or traders have become anxious or euphoric about the stock's potential.

For the Current Quarter, the growth estimate for Repros Therapeutics Inc.is -64.7%, while for the Next Quarter the stock growth estimate is -100%. The Weekly and Monthly Volatility stands at 30.97% and 14.87%. Over the trailing year, the stock is underperforming the S&P 500 by 19.31, and it's gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange.

Profitability analysis helps a great deal in making investment decision.

The company now has an insider ownership of 0.2 Percent and Institutional ownership of 20.1 Percent.

Liquidity ratios help investors to determine a company's ability to pay off its debts. The $0.51 level represents at least another 26.09% downside for the stock from its current price. The firm has a Return on Assets (ROA) value of -212.10%. The 50 day moving average moved up $0.30 whereas the 200 day average was up by +13.7721%. The average true range is a moving average, generally 14 days, of the true ranges.

Repros Therapeutics (NASDAQ:RPRX)'s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0.

Analysis of Earning Estimate for (next quarter, current year & next year) for Exelixis, Inc.

Repros reported that the clinical development expenses pertaining to Proellex® dropped for the quarter closed June 30, 2017, versus the prior year period, following decreased expenses related with the company's Phase 2b clinical studies for the treatment of endometriosis and uterine fibroids. They expect this year's earnings to rise 4.23% year-over-year to $2.96, followed by 2.03% growth in the next year to $3.02.

EPS growth for the next 5 years is 27.9 percent. The Beta for the stock stands at 0.38.

Looking forward, the company's quarterly earnings in the three months through September 2017 and in the quarter ending December 2017, reflecting -587747% and -624475% growth, respectively.

Medtronic plc (NYSE:MDT) now has a PEG ratio of 4.12 where as its P/E ratio is 26.83.

Repros Therapeutics Inc. (RPRX) showed volatility of 41.79% over the past week. The Volatility was noted at 3.48% in recent month and it observed Weekly Volatility of 3.03%.

Repros Therapeutics Inc. (NASDAQ:RPRX)'s latest quote $0.69 $-3.39 -7.43% will find technical support in $0.6 a share and a breakdown below this region would be a significantly bearish signal for Repros Therapeutics Inc. traders.

Investors and Traders continue to monitor technical levels of shares of Repros Therapeutics Inc.

Currently Repros Therapeutics (NASDAQ:RPRX)'s shares owned by insiders are 0.2%, whereas shares owned by institutional owners are 20.1%. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders.

Million Dollar Worth Of Gold Flushes Through Swiss Sewers Every Year
Amazon announce new waterproof Kindle Oasis